Figure 2.

Development of Obesity, Dyslipidemia, Glucose Intolerance, and Risk Biomarkers of Cardiovascular Disease

(A) Body weights were obtained at baseline and every 4 weeks throughout the 20-week study. Lipid profiling was performed at baseline and at 4, 12, and 20 weeks. (B) Total cholesterol (TC), (C) low-density lipoprotein (LDL), and (D) ratio of TC to high-density lipoprotein (HDL) were measured. At 20 weeks, conscious intravenous (IV) glucose tolerance testing was performed in overnight fasted minipigs. (E) Glucose levels were measured from timed blood samples obtained over 60 min following IV glucose administration. (F) The natural log (Ln) of glucose was determined 5 to 30 min following IV glucose administration was calculated. (G) Insulin levels were measured from timed blood samples obtained over 60 min following IV glucose administration. (H) Circulating plasma 8-isoprostane levels were measured at baseline and at 4, 12, and 20 weeks. (I) Serum endothelin (ET)-1 levels were measured at baseline and at 4, 12, and 20 weeks. Values are mean ± SEM; ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001, for significantly different versus control. Numbers in circles represent the number of animals analyzed. Abbreviation as in Figure 1.